Time to look at aquiring IPXL before news poors in. ENDP-IPXL (high growth) prescrip success
Impax under $30/share with low share count and $400 mil cash with no debt! A bid in the high $40's could make this happen for ENDP and project a new future. IPXL has a proprietary for Parkinsons going for approval later this month that is a game changer according to Barrons. IPXL a cash machine with generics now has 2 proprietary drugs nearing approval to give sustained high margin high demand drugs that will catch focus.